Literature DB >> 20551099

Cardiopulmonary exercise testing with right-heart catheterization in patients with systemic sclerosis.

Allan J Walkey1, Michael Ieong, Mir Alikhan, Harrison W Farber.   

Abstract

OBJECTIVE: To examine the role of cardiopulmonary exercise testing with right-heart catheterization (CPET/RHC) in patients with systemic sclerosis (SSc) with potentially multifactorial exertional limitation.
METHODS: This was a single-center retrospective cohort study of patients with SSc referred for CPET/RHC.
RESULTS: A total of 19 patients with SSc [subtypes: 10 limited, 5 diffuse, 1 systemic lupus erythematosus (SLE)/SSc overlap, and 3 with no subtype specified in the medical record] underwent CPET/RHC testing from February 2003 to February 2008. Of these patients, the primary limitations to exercise were found to be ventilatory (n = 6), deconditioning/cardiovascular (n = 6), pulmonary vascular (PVL; n = 3), and exercise-induced left ventricular diastolic dysfunction (exercise-LVDD; n = 4). No prior physical examination, pulmonary function test, imaging, or echocardiographic data reliably predicted the etiology of exercise limitation determined by CPET/RHC. Vital capacity and ventilatory equivalent for CO(2) did not differ during CPET testing between PVL and exercise-LVDD, limiting the utility of CPET alone for discriminating these etiologies of dyspnea. Exercise alveolar-arterial oxygen gradient was elevated in subjects shown to have PVL [median 48 mm Hg (interquartile range 45.3, 62.0)] compared to those with exercise-LVDD [26.0 (IQR 10.6, 36.0)] and deconditioning [13.9 (IQR 4.0, 16.4); p = 0.02]. Major therapeutic changes occurred in 11/19 (58%) subjects after CPET/RHC testing.
CONCLUSION: CPET/RHC testing in subjects with SSc and potentially multifactorial dyspnea adds potentially useful diagnostic information unavailable from noninvasive testing.

Entities:  

Mesh:

Year:  2010        PMID: 20551099     DOI: 10.3899/jrheum.091424

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  5 in total

1.  A prediction model for progressive disease in systemic sclerosis.

Authors:  Jessica Meijs; Anne A Schouffoer; Nina Ajmone Marsan; Theo Stijnen; Hein Putter; Maarten K Ninaber; Tom W J Huizinga; Jeska K de Vries-Bouwstra
Journal:  RMD Open       Date:  2015-12-01

2.  Cardiopulmonary exercise testing and prognosis in patients with systemic sclerosis without baseline pulmonary hypertension: a prospective cohort study.

Authors:  Vasiliki-Kalliopi Bournia; Anastasios Kallianos; Stylianos Panopoulos; Elias Gialafos; Lemonia Velentza; Panayiotis G Vlachoyiannopoulos; Petros P Sfikakis; Georgia Trakada
Journal:  Rheumatol Int       Date:  2021-06-29       Impact factor: 2.631

3.  An explanatory model of functional exercise capacity in patients with systemic sclerosis: considerations for rehabilitation programs.

Authors:  Agnaldo José Lopes; Arthur de Sá Ferreira; Tatiana Rafaela Lemos Lima; Sara Lucia Silveira Menezes; Fernando Silva Guimarães
Journal:  J Phys Ther Sci       Date:  2016-02-29

4.  Prognostic value of cardiopulmonary exercise testing in patients with systemic sclerosis.

Authors:  Ralf Ewert; Till Ittermann; Dirk Habedank; Matthias Held; Tobias J Lange; Michael Halank; Jörg Winkler; Sven Gläser; Horst Olschewski; Gabor Kovacs
Journal:  BMC Pulm Med       Date:  2019-11-29       Impact factor: 3.317

Review 5.  Advances in the management of pulmonary arterial hypertension.

Authors:  Himanshu Deshwal; Tatiana Weinstein; Roxana Sulica
Journal:  J Investig Med       Date:  2021-10       Impact factor: 2.895

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.